This Investigation is to be performed for the purpose of assessing the following information in the long-term post-marketing daily medical practice in the patients who receive REUMATOLEX 2 mg Capsule for the treatment of Rheumatoid Arthritis (RA) at the dose higher than 8 mg/week.
- Condition of occurrence of ADRs
- Factors considered to affect safety
- Verification of efficacy
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01414257?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
